ROIVANT SCIENCES
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.
ROIVANT SCIENCES
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Product Research
Founded:
2014-05-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.roivant.com
Total Employee:
501+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.09 B USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Global Site Tag Nginx Amazon
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-02-26 | Silicon Therapeutics | Silicon Therapeutics acquired by Roivant Sciences | 450 M USD |
Investors List
Eventide
Eventide investment in Post-IPO Equity - Roivant Sciences
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Post-IPO Equity - Roivant Sciences
Viking Global Investors
Viking Global Investors investment in Post-IPO Equity - Roivant Sciences
RTW Investments LLC
RTW Investments LLC investment in Post-IPO Equity - Roivant Sciences
Patient Square Capital
Patient Square Capital investment in Post-IPO Equity - Roivant Sciences
Palantir Technologies
Palantir Technologies investment in Post-IPO Equity - Roivant Sciences
Dainippon Sumitomo Pharma
Dainippon Sumitomo Pharma investment in Post-IPO Equity - Roivant Sciences
Suvretta Capital Management
Suvretta Capital Management investment in Post-IPO Equity - Roivant Sciences
SoftBank Capital
SoftBank Capital investment in Post-IPO Equity - Roivant Sciences
Novaquest Capital Management
Novaquest Capital Management investment in Private Equity Round - Roivant Sciences
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-11-03 | Medallion | Roivant Sciences investment in Series B - Medallion | 30 M USD |
| 2021-11-01 | gen-t | Roivant Sciences investment in Pre Seed Round - gen-t | 2 M USD |
| 2021-08-02 | Immunovant | Roivant Sciences investment in Post-IPO Equity - Immunovant | 200 M USD |
| 2020-10-08 | Datavant | Roivant Sciences investment in Series B - Datavant | 40 M USD |
| 2018-04-30 | Datavant | Roivant Sciences investment in Venture Round - Datavant | 40.5 M USD |
| 2017-10-02 | Arbutus Biopharma | Roivant Sciences investment in Post-IPO Equity - Arbutus Biopharma | 116.4 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-05-02 | Roivant Appoints Chief Development Officer and Announces Multiple Collaborations in Targeted Protein Degradation |
Official Site Inspections
http://www.roivant.com Semrush global rank: 836.93 K Semrush visits lastest month: 45.72 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Roivant Sciences"
Roivant
Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. … “Mosliciguat has the incredibly rare advantage of …See details»
Corporate Responsibility | Roivant
Roivant Social Ventures (RSV), a 501(c)3 social impact organization created by Roivant in 2020, envisions a future where every person is born with the right and ability to access medicine and medical care. RSV partners with innovative …See details»
Roivant Sciences - Wikipedia
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of BostonSee details»
Roivant Corporate Overview
Capital for Roivant with potential for additional shareholder return. Ongoing Capital Return • Cash, cash equivalents, restricted cash and marketable securities of $5.4BN as of Sep. 30, 2024 • …See details»
Roivant Corporate Overview
6 2028 Top US I&I Markets1 Additional Growth Markets Psoriasis $21.5 billion Graves' Disease ~116K US Incident Pop. Atopic Dermatitis $16.7 billion Thyroid Eye Disease ~8-18K New US …See details»
Roivant Sciences | White Rose Wiki
Apr 7, 2014 ¶Roivant Sciences. Roivant Sciences is an American-Swiss pharmaceutical and biotechnology company based in New York City, with offices in Boston, Massachusetts and …See details»
Roivant Sciences - Crunchbase Company Profile
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates. Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to …See details»
Roivant Social Ventures
Roivant Social Ventures (RSV) is a social impact organization that invests in health technologies and new therapeutics that lead to systemic improvements to health equity. We invest in new technologies, incubate innovative companies, …See details»
Roivant Sciences GmbH – Swiss Biotech
Roivant delivers R&D solutions to the biopharmaceutical industry and academic institutions through partnerships designed to realize the full potential of promising biomedical research. ...See details»
Leadership | Roivant - Roivant Sciences
Alex Gasner serves as the Executive Vice President of Roivant Health, where he leads new investments and company creation in healthtech. Mr. Gasner joined Roivant in November, 2017, and previously served as Head of Corporate …See details»
Roivant Sciences - Overview, News & Similar companies - ZoomInfo
Roivant Sciences contact info: Phone number: +44 2074003347 Website: www.roivant.com What does Roivant Sciences do? Founded in 2014 and headquartered in London, Roivant Sciences …See details»
Our Values - Roivant IT Handbook
CREDIT. Roivant IT’s six core values are 🤝 Collaboration, 📈 Results, ⏱️ Efficiency, 🌐 Diversity, Inclusion & Belonging, 👣 Iteration, and 👁️ Transparency, and together they spell the CREDIT we …See details»
Roivant - Products, Competitors, Financials, Employees, …
Roivant's headquarters is located at 151 W 42nd Street, New York. What is Roivant's latest funding round? ... The organization specializes in drug discovery, diagnostics development, …See details»
How Does Roivant Sciences Work? – CBM
Dec 19, 2024 Roivant Sciences operates as a biopharmaceutical company that specializes in acquiring and developing late-stage drug candidates across multiple therapeutic areas. The …See details»
roivant.com Reviews: Is this site a scam or legit?
Roivant.com Review. The Scam Detector website Validator gives roivant.com one of the higher trust scores on the platform: 86.It signals that the business is best defined by the following …See details»
Our Companies | Roivant
A career at Roivant is filled with remarkable growth opportunities for those tackling the most significant challenges in science and technology. See available positions. Pipeline. Our …See details»
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Yahoo Finance
4 days ago Shares of Roivant Sciences (NASDAQ:ROIV) rallied on Wednesday, ending the day up by 3.5 percent at $11.83 each. Year-to-date, the company’s stock price grew by 4.22 …See details»
Roivant Sciences - Funding, Financials, Valuation & Investors
Roivant Sciences 's most notable exits include Immunovant and Arbutus Biopharma. Which industries has this organization had the most exits in? Show . Immunovant Immunovant is a …See details»
Careers | Roivant
At Roivant, we employ the brightest minds from various industries and backgrounds, united by our mission to develop and deliver life-changing medicines to patients faster and more efficiently. …See details»
Earnings call: Roivant reveals Q4 2023 results and strategic growth ...
May 30, 2024 Roivant ended the fiscal year with strong cash reserves and a $1.5 billion share repurchase program. CEO Matt Gline discussed the launch of VTAMA, pipeline updates, and …See details»